Browse the evidence

GLP-1/Apelin hybrid peptides (ELA, ELA-Lys12, ELA-Lys38) significantly improve glucose tolerance and insulin secretion in both lean and high-fat-fed mice, with effects lasting up to 21 hours for acylated forms.

These hybrid peptides effectively lower blood glucose levels in mice for up to 21 hours, outperforming single-target approaches in duration. This suggests potential for less frequent dosing in diabetes management, though human trials are required.

GLP-1/Apelin hybrid peptides enhance beta-cell proliferation and protect against cytokine-induced apoptosis, contributing to beta-cell survival.

These hybrid peptides show promise in protecting beta-cells from stress and promoting their growth in laboratory settings. This could translate to better long-term diabetes management by preserving the body's natural insulin production capacity.

GIP receptor (GIPR) agonism suppresses inflammation-induced conditioned taste avoidance (aversion) by attenuating the activity of parabrachial CGRP neurons, while simultaneously enhancing inflammation-induced anorexia via distinct dorsal vagal complex (DVC) circuits.

If you are experiencing sickness-induced nausea and loss of appetite, standard anti-nausea drugs might not stop the feeling of aversion, and standard anti-inflammatories might not stop the nausea. This research suggests that GIP-based therapies could specifically target the 'sickness feeling' (aversion) via brain circuits, potentially allowing patients to feel better without necessarily worsening their lack of appetite, though it does increase food suppression. This is currently experimental in mice.

Tirzepatide use is associated with a significantly increased risk of gastrointestinal adverse events (GIAEs), with nausea and diarrhea being the most frequent, and eructation and impaired gastric emptying showing the highest disproportionality.

If you start tirzepatide, expect gastrointestinal side effects like nausea or diarrhea, especially in the first few months. The risk is higher if you are male, over 65, have Type 2 Diabetes, or take other medications. Working with your doctor to start with a low dose and increase it slowly can help your body adjust and reduce these side effects.

Gut microbiota dysbiosis in obesity drives hypertension through intestinal barrier dysfunction, allowing lipopolysaccharide (LPS) translocation that triggers systemic inflammation and vascular damage.

Your gut health may be contributing to your high blood pressure. While medication is important, focusing on a diet that supports a diverse microbiome (high fiber, fermented foods) and managing weight can help restore gut barrier integrity and reduce inflammation, potentially lowering blood pressure.

Short-chain fatty acids (SCFAs) produced by gut bacteria have complex effects: while generally beneficial for blood pressure regulation via GPCR activation, increased production in obesity may contribute to calorie harvest and weight gain.

Fiber is good for your heart, but if you are struggling with weight, be aware that your gut bacteria might be extracting more calories from your food. Focus on a balanced diet rather than just maximizing fiber intake if weight loss is a primary goal.

Online marketing of GLP-1 receptor agonists as 'weight loss injections' creates unrealistic expectations and encourages off-label, non-medical use, posing significant public health risks.

Be skeptical of online content that promotes GLP-1 injections as 'weight loss injections' without mentioning medical indications, side effects, or the need for a prescription. These are serious medications for obesity management, not cosmetic shortcuts. Consult a healthcare provider to determine if you are a suitable candidate and to understand the risks and benefits.

Activation of the mitochondrial unfolded protein response (UPRmt) in adipocytes serves as a critical adaptive mechanism to restore mitochondrial proteostasis and mitigate dysfunction during metabolic stress, offering a potential therapeutic strategy for obesity and related metabolic disorders.

This paper highlights that your body has a sophisticated internal repair system (UPRmt) that activates when mitochondria are stressed. While there is no specific 'dose' provided, the text suggests that factors like cold exposure, exercise, and specific hormonal signals can induce 'browning' of white fat and activate these pathways. To support this mechanism, focus on activities known to stimulate mitochondrial biogenesis and stress adaptation, such as regular physical exercise and potentially cold exposure, as these are linked to the activation of UPRmt and improved metabolic health in the reviewed literature.

Greater lean body mass loss with tirzepatide is mechanistically linked to its dual GLP-1/GIP receptor agonism, as GIP receptors are broadly expressed in immune, stromal, and vascular muscle compartments, unlike the more restricted GLP-1 receptor.

Tirzepatide's unique ability to activate GIP receptors may affect muscle tissue differently than semaglutide by influencing immune and vascular cells in muscle, potentially contributing to greater muscle loss.

Improvement in cellulite severity is not significantly correlated with changes in body weight or fat mass, indicating that local structural and metabolic-dermal interventions are primary drivers of cellulite reduction rather than systemic adiposity loss.

If you are trying to reduce cellulite, relying solely on weight loss or fat loss may not yield visible improvements in skin texture. This study suggests that combining systemic metabolic health (e.g., managing insulin/inflammation) with targeted local treatments (like specific topical formulations) is more effective for cellulite than weight loss alone. Focus on local tissue health and metabolic balance rather than just the scale.

Gut microbiota dysbiosis impairs GLP-1 secretion, contributing to the progression of degenerative musculoskeletal diseases (osteoarthritis, osteoporosis, sarcopenia, and intervertebral disc degeneration).

Degenerative joint and muscle issues in aging may be linked to gut health. Restoring a healthy gut microbiome through diet (fiber/prebiotics), probiotics, or fecal microbiota transplantation (FMT) may help restore natural GLP-1 levels, potentially slowing disease progression. This is a supportive strategy, not a standalone cure.

GLP-1 exerts protective effects on musculoskeletal tissues (bone, cartilage, muscle, disc) by reducing inflammation, oxidative stress, and apoptosis.

Maintaining healthy GLP-1 levels (via gut health) may help protect joints and muscles from age-related degeneration by reducing inflammation and cell death.

Current economic models often undervalue incretin therapies by excluding downstream benefits (e.g., reduced MACE, sleep apnea, osteoarthritis), leading to high ICERs that may exceed willingness-to-pay thresholds without price reductions.

For payers, these drugs are expensive. However, if you account for long-term health savings (fewer heart attacks, surgeries), they can be cost-effective, especially if the price is lowered or targeted at high-risk patients.

Diet quality among U.S. adults improved modestly between 1999 and 2020.

Practitioners should note a modest improvement in diet quality over the past two decades.

The proportion of U.S. adults with poor diet quality remains high.

Practitioners should be aware that many adults still have poor diet quality.

Dietary disparities persist or are worsening among U.S. adults.

Practitioners should focus on addressing dietary disparities in their communities.

GLP-1 receptor agonists delay gastric emptying via peripheral and central nervous system pathways, creating a significant risk of retained gastric contents and pulmonary aspiration during anesthesia even when standard preoperative fasting guidelines are followed.

If you take a GLP-1 medication (like Ozempic, Wegovy, or Mounjaro) and are scheduled for surgery, you must inform your anesthesiologist and endocrinologist. Do not assume standard fasting rules apply. Your stomach may still contain food, increasing the risk of serious lung complications during anesthesia. Your care team may need to adjust your fasting instructions, postpone elective surgery, or use special techniques to protect your airway.

Short-acting GLP-1 RAs cause more pronounced delays in gastric emptying than long-acting agents, although long-acting agents may still pose aspiration risks due to residual effects depending on dose and treatment duration.

Know which GLP-1 medication you take. Short-acting drugs (like Byetta or Trulicity's short-acting cousin) tend to slow your stomach more than long-acting ones (like Ozempic or Mounjaro). However, even long-acting drugs can keep food in your stomach if you took a dose recently. Always tell your surgical team exactly when you took your last dose.

In non-beta tissues (liver, kidney, skeletal muscle, adipose), the mitochondrial benefits of GLP-1RAs are likely a combination of direct receptor signaling and indirect systemic improvements such as weight loss and reduced inflammation.

While GLP-1 drugs improve mitochondrial health in organs like the liver and muscles, these benefits are partly due to the overall reduction in body weight and blood sugar. It is a combined effect of losing weight and the drug's direct action on cells.

The proportion of new users of semaglutide (Ozempic ® ) with a record of type 2 diabetes (T2D) declined from 99% in 2018 to only 67% in 2022, before increasing again to 87% in 2023.

Practitioners should note the changing demographics of semaglutide users, indicating a shift towards off-label use.

Most initiators of semaglutide (Ozempic ® ) with T2D had suboptimal glucose control, with 83% having an HbA1c ≥ 48 mmol/mol.

Practitioners should be aware that many T2D patients starting semaglutide may not have optimal glucose control.

Atomoxetine and oxybutynin combination reduces AHI in OSA patients but may increase heart rate and blood pressure, requiring risk/benefit assessment.

A combination of atomoxetine and oxybutynin can slightly reduce sleep apnea severity, but it may raise heart rate and blood pressure. Because the benefit is small and risks exist, it is not a first-line treatment and requires careful medical supervision.

25.3% of plastic surgeons prescribed or utilized GLP-1 agonists in their practice.

A significant portion of plastic surgeons are incorporating GLP-1 agonists into their practice.

57.8% of plastic surgeons believe GLP-1 agonists are profitable for business.

Many plastic surgeons see GLP-1 agonists as a profitable addition to their practice.